Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 1, 2013Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia™ During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October
Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal TrainsSM sponsored by Magnolia™, which aim...
-
Sep 16, 2013- Companies Initiate Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology...
-
Aug 8, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound...
-
Jul 8, 2013The Eisai Women’s Oncology Program - MagnoliaTM, CancerCare®, Cancer Support CommunitySM and Meals On Wheels Association of AmericaTM Are Working Together to Help Ease the Stress of Those Living with Breast Cancer in New Jersey
Woodcliff Lake, NJ, July 8, 2013- Magnolia Meals at Home™, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in Essex...
-
May 16, 2013
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during...
-
May 16, 2013Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)
Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the...
-
May 9, 2013
Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation...
-
Mar 21, 2013- Companies to Provide Open Access to Information with Goal of Accelerating Discovery of Medicines for People Living with Difficult-to-Treat Cancers -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, and BGI,...
-
Feb 21, 2013
Woodcliff Lake, NJ and Montreal, Quebec, February 21, 2013 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX)...
-
Feb 14, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug...